Summary by Moomoo AI
On February 14, 2024, Ginkgo Bioworks Holdings, Inc. reported an amendment to the Schedule 13D filing by Jason Kelly, indicating a change in his ownership stake. The amendment, which is the third of its kind following previous filings, reflects a decrease in Kelly's percentage of Class A Common Stock ownership due to 'sell-to-cover' transactions to meet tax withholding obligations and sales under Rule 10b5-1 compliant plans. As of the amendment date, Kelly beneficially owns 85,752,333 shares, representing 5.0% of the company's Class A Common Stock, a reduction from his prior holdings. This includes both Class A and Class B shares, with the latter convertible to Class A on a one-to-one basis. The filing also marks an exit for Kelly as he ceases to be the beneficial owner of more than five percent of Ginkgo Bioworks' outstanding Class A shares. The transactions leading to this amendment occurred between December 20, 2023, and January 4, 2024, with sales executed through open market transactions at varying prices.